The future of oncology in the Middle East

In this in -depth exploration, Olfat Berro, head of the Middle East area for Roche Pharmaceuticals, examines how technological innovations and strategic associations are transforming cancer attention in the Middle East. Switching about 20 years of health experience, Berro highlights the change of standardized treatments to personalized medicine and describes how collaboration efforts are creating more accessible oncological care systems focused on the patient.

When I started my career in medical care for more than 20 years, cancer was a diagnosis that Offe left patients and their families feeling helpless. At that time, most of the treatment options were limited and uniform
-A unique approach for all that did little to address the complex and individual realities of those who face this disease. I remember listening to patients about the weight of each diagnosis, the struggle to find any hope in a system that could only survive standardized treatments and the excessive need for better solutions. Today, that story has changed dramatically.

In my experience in the pharmaceutical industry, I have witnessed an extraordinary transformation. The appearance of technologies such as artificial intelligence, precision diagnosis and immune therapies, as well as immune therapies, has not only redefined what is possible in cancer care, but also has reformed our entire approach.

From a traditional trip to a personalized
Advances in science have turned what once could make us feel helpless in a trip of hope and possibility. This cancer trip is reflected in the change of uniform treatment protocols to approaches that adapt attention to the individual. We now recognize that cancer is not a single disease, but a general term for more than 200 different conditions, each with its own genetic and molecular fingerprint. This realization has raided the path for personalized medicine, where treatments are customized to address the unique biology of each patient’s tumor. In the Middle East, the impact of thesis innovations, in part is significant. In our region, where early detection has a historical challenge due to different levels of health infrastructure, the promise of precision oncology sacrifices a new hope. For example, in breast cancer, a main cause of mortality among women
– The advance of directed therapies has drastically improved survival rates. Similarly, in lung cancer, the use of molecular profiles allowed oncologists to choose much more effective treatments than traditional methods, significantly improving patient’s results.

Take advantage of technology and data for better cancer results
Technological innovation is in the heart of this revolution. Artificial intelligence and data analysis are transforming each stage of cancer care, from early diagnosis to the optimization of the treatment and monitoring of patients. Image tools with AI, for example, are now capable of detecting patterns in scans that can be invisible to the human eye, allowing doctors to identify tumors at their earliest stage and with greater precision. It also has a leg change towards the non -invasive diagnosis with liquid biopsies, a simple blood test that can detect small traces of biomarkers related to cancer, which allow doctors to monitor cancer in real time and treatment.

Beyond modern technology, the data plays a fundamental role in the configuration of the future of oncology. By taking advantage of fixed quantities of the real world of clinical trials, electronic health records and patient records, we are better equipped to understand treatment responses and refine therapeutic strategies. This data -based approach means that each new advance is not only a scientific achievement, but also a step towards more efficient and effective patient care. In the Middle East, where timely access to attention can significantly alter the results, these innovations are especially critical.

The importance of associations in the Middle East
Transforming cancer attention is not just about innovation, it is about ensuring that progress reaches the people who need them the most. A truly sustainable health system must provide timely access to avant -garde treatments while strengthening its ability to face future challenges. This can only be achieved through collaboration.

Throughout the Middle East, Roche recognizes his role as a medical care partner. Multisectoral collaborations with interested parties of health are essential to support the entire patient’s trip from awareness and guarantee early detection to take advantage of data for personalized care, improve treatment results.

Now more than ever, working together is essential to create stronger, more resistant and receptive health systems. The trip begins with public awareness. Empowering communities with knowledge about cancer prevention and early detection is the first step towards early intervention. When working closely with the Iraqi government to advance the results of medical care, one of our main priorities is to increase awareness for early detection and support community education for diseases such as oncology. These initiatives help patients and their families understand the importance of regular controls.

However, consciousness alone is not enough: it must be backed by early detection tools and technologies. IA -driven detection solutions are playing a transformative role in the identification of cancer in their first internships with remarkable precision. The collaboration projects with Microsoft & Lunit Global in Iraq and Egypt have introduced tools of writings based on the mammography analysis with up to 96% precision, an innovation that significantly reduces the late savings diagnoses.

Beyond detection, real world data is redefining personalized attention. By leveraging advanced analysis, health professionals can refine the treatment pathways, optimize the allocation of resources and go beyond unique size approaches. In Bahrain, collaboration with the national regulatory authorities of Health (NHRA), advance in clinical research and take advantage of real world data to strengthen pharmacovigilance and regulatory frameworks. These efforts ensure that treatments are not only innovative, but also adapt precisely to the individual needs of patients, leading to a better response and a better quality of life.

Of course, only the most advanced treatments make sense if patients cannot access them. Ensuring availability and affordability is an cornerstone or sustainable medical care. Strategic associations in our region have led to the development of financing models and infrastructure improvements that make avant -garde treatments available to patients. Through our collaboration in Lebanon, patient support programs (PSPS) have helped thousands or patients access to critical treatments, ensuring the continuity of care. Early access initiatives are also joining gaps, ensuring that patients benefit from the latest advances in cancer therapy.

Ultimately, the future of oncology in the Middle East is a shared responsibility. When we work along with trust, common values ​​and a clear approach to the long -term impact, each scientific advance can be matched by the infrastructure and the necessary policies to provide attention to save lives. This collective effort guarantees that each patient benefits from the highest level of care.

Looking to the future: a call to collective action
In the Middle East, where the landscapes of medical care are diverse and evolve rapidly, our mission is clear: dismantling barriers and building resistant and patient -centered systems that make early detection reality and personalized treatments for all. Each initiative, from pioneer detection programs to the integration of advanced diagnoses in daily care, demonstrates our commitment to transform cancer attention of a challenging diagnosis into a trip of hope.

Our approach is based on collaboration. We know that when the partners of related ideas, medical care providers and the defense groups of patients that unite the forces, the collective impact far exceeds what any organization can achieve. I have witnessed how associations throughout the region have improved the results and created a future in which innovative oncology solutions become the standard, not the exception. Together, taking advantage of technology, promoting associations and keeping patients at the center of each decision,
We can build a future where cancer attention is not only advanced and accessible, but it is truly transformative for coming generations.